More than 130 suppliers

In-house tech support

Call +31 (0)26 326 44 50

Bio-Connect

Products
Products
Antibodies
Chemicals
Proteins / Signaling Molecules
Assays
DNA / RNA / Vectors
Cell Culture
Genome Editing and Engineering
Molecular Biology
Lysates / Extracts
Expression
Labware / Accesories
Body Products
Technique Specific Products
Arrays / Slides
All product groups
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Research
Research
Cancer research
Epigenetics research
Immunology and inflammation research
Neuroscience research
Virology research
SARS-CoV-2
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Industries
Suppliers

Tech support
News
About us
About us
Our company
Our people
Divisions
Vacatures
Events
Promotions
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
FAQ
Contact

ProductsBack/OTX-015 [202590-98-5]

OTX-015 [202590-98-5]

O7992

Estimated Purity≥98%

DownloadDatasheet

Product group Chemicals

Overview

Supplier
LKT Laboratories
Product Name
OTX-015 [202590-98-5]
Delivery Days Customer
7
Estimated Purity
≥98%
Format
DMSO: ≥ 49 mg/mL
Scientific Description
BRD2/3/4 inhibitor.; OTX015; Y-803; Birabresib; MK-8626; MK8628
Storage Instruction
-20°C
UNSPSC
12352200

References

Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res. 2015 Apr 1;21(7):1628-38.PMID: 25633213. Noel JK, Iwata K, Ooike S, et al. Development of the BET bromodomains inhibitor OTX015. Mol Cancer Ther. 2013 Nov:12;C244. Boi M, Todaro M, Vurchio V, et al. OTX015, a bromodomains and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. Mol Cancer Ther. 2013 Nov:12;A219.